KZA 0.00% 8.0¢ kazia therapeutics limited

SNO 26th Annual Meeting, page-2

  1. 1,120 Posts.
    lightbulb Created with Sketch. 762
    26th Annual Meeting and Education Day of the Society for Neuro-Oncology November 18 - 21, 2021

    IMO Kazia management will wait for the final data from paxalisib phase2 Kazia / Danna-Farber GBM trial results, and then submit a New Drug Application (NDA) submission, which may result in a faster product approval for paxalisib.

    Regards.



 
watchlist Created with Sketch. Add KZA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.